Kellie J Goodlet, Pharm.D., BCPS, BCIDP

Assistant Professor
Glendale, AZ

Home / Academics / Our Faculty / Kellie J Goodlet, Pharm.D., BCPS, BCIDP

Assistant Professor

Glendale, AZ

College of Pharmacy
Glendale Campus

Pharmacy Practice


Send Me
a Message


University of Arizona | 2015 | Pharm.D.
University of Arizona (Microbiology) | 2011 | B.S.

Courses Taught

Integrated Sequence 8 (infectious diseases therapeutics and pharmacokinetics)

Integrated Sequence 9

Professional Skills Development 7


Dr. Kellie J. Goodlet conducts research relating to the optimization of antimicrobials and associated therapies in clinical infectious diseases practice. In addition to her collaborations with colleagues at Midwestern University and St. Joseph's Hospital and Medical Center, Dr. Goodlet also offers an Advanced Pharmacy Practice Experience (APPE) rotation which allows third year pharmacy students to participate in infectious diseases research.

Research Interests

Antimicrobial Stewardship: Antimicrobial stewardship involves promoting the minimal necessary antimicrobial use to improve patient outcomes, decrease microbial resistance and adverse effects, and reduce costs. Stewardship principles include treating only infected patients using the least broad-spectrum agents possible, for the shortest effective duration. Rapid de-escalation of broad-spectrum antimicrobials and "diagnostic stewardship" are additional focuses.

Multi-Drug Resistance: Antimicrobial resistance is a global healthcare concern. Patients infected with MDR/XDR organisms face limited treatment options. Additionally, different resistance mechanisms/genotypes often dictate therapy. Antibiotic optimization strategies, including multi-model antibiotic administration, dose-optimization, combination therapy, and utilization of novel antimicrobials may result in successful eradication of infection.

Infection Management in the Immunosuppressed:  Transplant recipients and other highly immunocompromised populations are at risk for infection with organisms rarely seen among immune competent persons, for which there exists a paucity of data.

Antimicrobial Safety:  Even among well-tolerated antimicrobial classes, significant adverse effects, including potential selection of multi-drug resistant organisms and increased infection risk, are possible. Conversely, for many antimicrobials, the risk and magnitude of adverse reactions is overstated, leading clinicians to overlook potentially beneficial therapies. Rational assessments of the risks and benefits of antimicrobials are needed to inform optimal antimicrobial selection.


Grimes R, Cherrier L, Nasar A, Nailor MD, Walia R, Goodlet KJ. Outcomes of nontuberculous mycobacteria isolation among lung transplant recipients: a matched case-control with retrospective cohort study. Am J Health Syst Pharm. 2021. Epub ahead of print.

Truong CN, Nailor MD, Walia R, Cherrier L, Nasar A, Goodlet KJ. Universal lifelong fungal prophylaxis and risk of coccidioidomycosis in lung transplant recipients living in an endemic area. Clin Infect Dis. 2021. Epub ahead of print. 

Patel J, Christofferson N, Goodlet KJ. Pharmacist-provided SARS-CoV-2 testing targeting a majority-Hispanic community during the early COVID-19 pandemic: results of a patient perception survey. J Am Pharm Assoc (2003). 2021. Epub ahead of print.

Goodlet KJ, Raney E, Buckley K, Afolabi T, Davis L, Fettkether RM, Jones M, Larson S, Tennant S. Impact of the COVID-19 pandemic on the emotional intelligence of student pharmacist leadersAm J Pharm Educ. 2021. Epub ahead of print.

Fairman KA, Goodlet KJ, Rucker JD, Zawadzki RS. Unexplained mortality during the US COVID-19 pandemic: retrospective analysis of death certificate data and critical assessment of excess death calculations. BMJ Open. 2021;11:e050361.

Goodlet KJ, Tan E, Knutson L, Nailor MD. Impact of the FilmArray meningitis/encephalitis panel on antimicrobial duration among patients with suspected central nervous system infection. Diagn Microbiol Infect Dis. 2021;100:115394.

Goodlet KJ, Tokman S, Nasar A, Cherrier L, Walia R, Nailor MD. Nocardia prophylaxis, treatment, and outcomes of infection in lung transplant recipients: a matched case-control study. Transpl Infect Dis. 2021;23:e13478. 

Lutz S, Heberling M, Goodlet KJ. Patient perspectives of pharmacists prescribing HIV pre-exposure prophylaxis: a survey of patients receiving antiretroviral therapyJ Am Pharm Assoc (2003). 2021;61:e75-9.. 

Goodlet KJ, Bansal S, Arjuna A, Nailor MD, Buddhdev B, Abdelrazek H, et al. COVID-19 in a lung transplant recipient: exploring the diagnostic role of circulating exosomes and the clinical impact of advanced immunosuppression. Transpl Infect Dis. 2021;23:e13480.

Goodlet KJ, Gore S, Stoffel M, Nailor MD. Making the transition from pharmacy resident to independent practitionerAm J Health Syst Pharm. 2021;78:14-7.

Buckley K, Bowman B, Raney E, Afolabi T, Fettkether RM, Larson S, Tennant S, Goodlet KJEnhancing the emotional intelligence of student leaders within an accelerated pharmacy programAm J Pharm Educ. 2020;84:1476-81.

Goodlet KJ, Nailor MD. Involving pharmacy students in clinical research: tips and best practicesAm J Health Syst Pharm. 2020;77:1945-8.

Goodlet KJ, Raymond A, Schlosser EG. A practical guide to feedback in the workplace: transitioning from learner to independent practitionerAm J Health Syst Pharm. 2020;77:1196-9.

Goodlet KJ, Spadafora K, Walia R, Nailor MD. Updates in the treatment of breakthrough mold infectionsCurr Fungal Infect Rep. 2020;14:153-65.

Roberts EP, Roberts BS, Burns A, Goodlet KJ, Chapman A, Cyphers R, Atkinson J. Prevalence and dental professional awareness of antibiotic self-medication among older adults: Implications for dental educationJ Dent Educ. 2020;87:1126-35.

Goodlet KJ, Cameron EA, Nailor MD. Low sensitivity of procalcitonin for bacteremia at an academic medical center: a cautionary tale for antimicrobial stewardshipOpen Forum Infect Dis. 2020;7:ofaa096.

Burns A, Goodlet KJ, Chapman A, Roberts EP. A case report of self-medication with over-the-counter fish antibiotic: implications for pharmacists. J Am Pharm Assoc. 2020;60:e121-3.

Afolabi TM, Goodlet KJ, Fairman KA. Association of antibiotic treatment duration with first recurrence of uncomplicated urinary tract infection in pediatric patients. Ann Pharmacother. 2020;54:757-66.

Fairman KA, Romanet D, Early NK, Goodlet KJEstimated cardiovascular risk and guideline-concordant primary prevention with statins: retrospective cross-sectional analyses of US ambulatory visits using competing algorithmsJ Cardiovasc Pharmacol Ther. 2020;25:27-36

Bath RM, Doering BE, Nailor MD, Goodlet KJPharmacotherapy-induced hepatitis B reactivation among patients with prior functional cure: a systematic review. Ann Pharmacother. 2019;53:294-310.

Goodlet KJ, Nailor MD, Omar A, Huang JL, LiPuma JJ, Walia R, Tokman S. Successful lung re-transplant in a patient with cepacia syndrome due to Burkholderia ambifariaJ Cyst Fibros. 2019;18:e1-e4. 

Goodlet KJ, Fairman KA. Adverse events associated with antibiotics and intravenous therapies for post-lyme disease syndrome in a commercially insured sample. Clin Infect Dis. 2018;67:1568-74.

Goodlet KJ, Benhalima FZ, Nailor MD. A systematic review of single-dose aminoglycoside therapy for urinary tract infection: is it time to resurrect an old strategy? Antimicrob Agents Chemother. 2018;63. pii: e02165-18.

Goodlet KJ, Zmarlicka MT, Peckham AM. Drug-drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugsCNS Spectr. 2019;24:287-312. 

Cherrier L, Nasar A, Goodlet KJ, Nailor MD, Tokman S, Chou S. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infectionAm J Transplant. 2018;18:3060-4. 

Bilinskaya A, Goodlet KJ, Nailor MD. Evaluation of a best practice alert to reduce unnecessary Clostridium difficile testing following receipt of a laxativeDiagn Microbiol Infect Dis. 2018;92:50-5. 

Almarzoky Abuhussain SS, Goodlet KJ, Nailor MD, Nicolau DP. Optimizing skin and skin structure infection outcomes: considerations of cost of careExpert Rev Pharmacoecon Outcomes Res. 2018;18:235-44.

Goodlet KJ, Nailor MD. Necessity of carbapenem use when prescribed per infectious diseases specialistsDiagn Microbiol Infect Dis. 2017;88:41-6.

Goodlet KJ, Nicolau DP, Nailor MD. In vitro comparison of ceftolozane-tazobactam to traditional beta-lactams and ceftolozane-tazobactam as an alternative to combination antimicrobial therapy for Pseudomonas aeruginosaAntimicrob Agents Chemother. 2017;61. pii: e01350-17.

Goodlet KJ, Nicolau DP, Nailor MD. Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infectionsTher Clin Risk Manag. 2016;12:1811-26. 

Goodlet KJ, Girotto JE. Optimal vaccine administration for patients undergoing chemotherapy. Conn Med. 2016;80:305-11. 


Infectious Diseases Society of America (IDSA)

Society of Infectious Diseases Pharmacists (SIDP)

American Society of Health-System Pharmacists (ASHP)

Infectious Diseases Educators Network (ID-EN)


Faculty Preceptor of the Year 2020, Midwestern University College of Pharmacy

Mentor of the Year 2019, Midwestern University College of Pharmacy

ASHP Foundation Student Research Award 2019 (senior author and research mentor to student recipient)

Kenneth A. Suarez Research Day 2019 – Pharmacology and Drug Development category winner (research mentor to student recipient)